Dicaris 150 mg Tablets (Levamisole)

What makes Dicaris 150 mg a specific rather than general choice?

Dicaris is a fixed-strength oral tablet containing 150 mg of levamisole. The main purchase decision is therefore not simply whether levamisole is of interest, but whether this exact tablet strength, dosage form and intended use match the plan discussed with a qualified health professional. A 150 mg tablet does not automatically provide the correct dose for every person or condition, and the available pack quantities should not be used to infer a treatment schedule.

Levamisole is an anthelmintic, meaning a medicine active against certain parasitic worms. It has also been studied or used in some settings for effects on immune activity. Those different contexts are not interchangeable, and Dicaris should not be treated as a general solution for every worm infection, skin problem or immune-related condition. Its association with potentially serious changes in white blood cell counts makes a clear clinical purpose and an appropriate monitoring plan particularly important.

Product identity and clinical context

Each Dicaris tablet contains 150 mg of levamisole and is taken by mouth. The supplied product identity is a tablet, not a liquid, chewable tablet, dispersible tablet or modified-release preparation. Keeping that distinction clear matters when comparing products because another formulation may allow different dosing flexibility or have different directions for use.

The catalogue context associates Dicaris with skin infection, leprosy, warts and lichen planus. These labels require careful interpretation. "Skin infection" is not a precise diagnosis, and levamisole is not a general antibacterial treatment. Leprosy requires specialist diagnosis and established multidrug treatment; levamisole must not be viewed as a replacement for that care. Uses involving warts or lichen planus may be off-label or supported differently across clinical settings. The exact intended use should therefore be confirmed rather than inferred from a broad catalogue label.

Levamisole also has recognised anthelmintic activity against certain intestinal worms, but its medicine class alone does not establish that it is appropriate for a particular parasite. Identifying the condition first is essential because different antiparasitic medicines act against different organisms.

Who should discuss Dicaris with a health professional?

Dicaris may be considered only after the reason for using levamisole is clear. A doctor or pharmacist can help distinguish between a parasitic infection, a dermatological condition and another problem that requires a different treatment. Important decision factors include:

• The diagnosis: symptoms alone may not identify the parasite or skin condition, and levamisole does not cover every possible cause.
• The proposed dose and schedule: the product supplies one 150 mg strength, but appropriate dosing can vary with the indication, age, body weight and clinical circumstances.
• Blood-related risk: levamisole can cause neutropenia or agranulocytosis, which are serious reductions in infection-fighting white blood cells.
• Previous treatment: the alternatives already tried, their results and any adverse effects can influence whether levamisole is a reasonable option.
• Pregnancy or breastfeeding: both require an individual assessment of potential benefit and risk.
• Age and body weight: paediatric anthelmintic dosing has been weight-based, so a fixed 150 mg tablet is not automatically suitable for a child.
• Monitoring: repeated or prolonged exposure may require blood-count monitoring and medical supervision.

These factors are relevant even when our ordering policy does not require a prescription. A checkout requirement and a clinical decision are separate matters: the absence of a prescription-submission step does not confirm that a medicine or dose is appropriate for an individual.

Levamisole's action and its practical meaning

Against susceptible worms, levamisole acts on nerve and muscle signalling, causing paralysis of the parasite so that it can be expelled. This mechanism helps explain why it can be useful against certain worms but not against every parasite. The responsible choice depends on the organism involved, not simply on selecting any medicine described as antiparasitic.

Levamisole has also been investigated for effects on immune-cell activity. That does not mean it generally "boosts" the immune system, nor does it establish that it will benefit every condition involving inflammation or immunity. Evidence, dosing and medical practice vary by indication, and immune effects may also contribute to clinically important risks. For this reason, treatment purpose and supervision matter more than broad descriptions such as "immune support".

The mechanism does not provide a reliable way to predict how quickly an individual will respond. It also does not justify extending a course, repeating a dose or using a larger pack without specific instructions.

Using the oral tablet safely

Dicaris should be taken only according to the directions provided for the intended use. The tablet contains 150 mg of levamisole, but available official records do not establish one universal schedule for all the conditions associated with the product. Do not create a dosing plan from the number of tablets in a pack or from directions written for a different levamisole product.

• Confirm the number of tablets per dose and the timing of each dose before starting.
• Take the tablet by mouth as directed and follow any product-specific instructions about food.
• Do not split or crush the tablet unless a qualified health professional confirms that this particular tablet can be divided and calculates the required amount.
• If a dose is missed, obtain advice rather than doubling the next dose.
• Keep any scheduled blood tests, especially when treatment involves repeated or prolonged dosing.
• Do not share the medicine, even when another person appears to have similar symptoms.

Store the tablets at room temperature between 15°C and 30°C in a dry place protected from light. Keep them out of reach of children. Before use, check the packaging, expiry date and supplied instructions, particularly if the product differs from a levamisole brand used previously.

Available strength and pack quantities

Our catalogue offers Dicaris only as 150 mg tablets. The available package quantities are 16, 32, 48, 60, 76 and 92 tablets. These are quantity choices, not different strengths or formulations. Selecting a larger package does not change the amount of levamisole in each tablet.

The appropriate quantity depends on a confirmed treatment plan. It would be misleading to label a particular pack as a "single-course" or "repeat-course" option without knowing the indication and dosing schedule. When comparing quantities, consider only the number required under the directions you have been given and avoid buying additional tablets on the assumption that treatment will need to be repeated.

Prices in our catalogue are presented in Australian dollars. The current package choices and corresponding prices can be reviewed during product selection without reproducing an offer grid in this guide.

What outcomes and timing can reasonably be expected?

There is no single response time that applies to every proposed use of Dicaris. An anthelmintic outcome depends on whether the parasite is susceptible, whether the diagnosis is correct and whether the prescribed dose is appropriate. A skin-related or immune-related use has a different evidence base and should not be assessed against the same expectations as treatment for a worm infection.

No response should be assumed after a particular number of tablets. Avoid repeating treatment simply because symptoms have not changed as quickly as expected. Persistent symptoms can reflect an incorrect diagnosis, reinfection, inadequate response or a condition that requires another type of care. A clinician can advise when follow-up, testing or a treatment change is appropriate.

Dicaris should not be presented as a quick fix, guaranteed cure or universally preferable option. A favourable decision depends on a clearly identified use and a balance between potential benefit and the medicine's blood-related and neurological risks.

Major safety priorities

The most important recognised safety concern with oral levamisole is agranulocytosis, a potentially serious reduction in a type of white blood cell needed to fight infection. Neutropenia, another reduction in white blood cells, may also occur. The risk is particularly important with repeated or prolonged dosing, and blood-count monitoring may be recommended during treatment.

Seek prompt medical advice if fever, chills, a persistent sore throat, mouth ulcers, unusual tiredness or other signs of infection develop. Unusual bruising or bleeding also warrants attention. These symptoms have many possible causes, but they should not be ignored during levamisole treatment.

• Pregnancy: adequate human pregnancy data are lacking. Established labelling advises use only when the expected benefit is judged to outweigh potential fetal risk. The decision, including whether treatment can be deferred beyond the first trimester, must be individualised.
• Breastfeeding: established advice recommends deciding between discontinuing breastfeeding and discontinuing levamisole because serious effects in a breastfed infant are possible.
• Children: established paediatric anthelmintic use has involved weight-based dosing of about 2.5-3 mg/kg as a single dose. The fixed 150 mg tablet therefore requires professional dose calculation and is not automatically suitable, even for a larger child.
• Driving and machinery: dizziness, lethargy or other neurological effects may impair alertness. Do not drive or operate machinery until the individual effect is known.
• Hypersensitivity: do not use levamisole if there is a known allergy to levamisole or another ingredient in the product.

An unspecified history of allergies is not, by itself, a levamisole-specific contraindication. However, the ingredients on the actual package should still be checked if there is a known allergy or intolerance.

Which interactions and precautions should be reviewed?

Before taking Dicaris, provide a doctor or pharmacist with a complete list of medicines, supplements and recent treatments. This is particularly important for medicines that can affect white blood cells, bone marrow or immune function because overlapping effects may increase risk or alter the monitoring plan. Do not stop another prescribed medicine solely because of a possible interaction; ask for an individual review.

Established oral levamisole information does not identify a diabetes-specific dose adjustment or a routine requirement for additional glucose monitoring. This does not remove the need to disclose diabetes or other long-term conditions, because the overall treatment plan and concurrent medicines still matter.

Alcohol, non-prescription products and complementary medicines should also be mentioned during an interaction check. If neurological symptoms, marked dizziness or signs of infection occur, further doses should not be taken until appropriate advice is obtained. Suspected adverse effects can be reported to the Therapeutic Goods Administration as well as discussed with a health professional.

Conditional comparison with other antiparasitic medicines

Dicaris should be compared with alternatives according to the diagnosed condition rather than by brand familiarity or pack price alone. Other anthelmintics are not direct substitutes for levamisole in every situation:

• Albendazole and Mebendazole are commonly used for particular intestinal worm infections, but their coverage and dosing vary by parasite.
• Pyrantel pamoate, including products sold under the Combantrin name, is a familiar option for certain intestinal worms such as threadworm. It has a different mechanism and dosing approach.
• Ivermectin, including Stromectol, is used for selected parasitic infections and is not interchangeable with levamisole solely because both are antiparasitic medicines.
• Piperazine is an older anthelmintic with a narrower place in contemporary treatment.
• Ergamisol is another brand name historically associated with levamisole, but a shared active ingredient does not guarantee identical strengths, excipients, approved uses or directions.

For a routine intestinal worm concern, an alternative with established activity against the identified worm may be more appropriate than Dicaris. For a skin-related use, comparing it only with worm medicines may miss more relevant dermatological treatments. Readers considering the wider field can browse our Antiparasitics category. The category also includes medicines for parasites other than worms; for example, Chloroquine has a different clinical role and is not an alternative anthelmintic for ordinary intestinal worms.

Australian access and regulatory context

An Australian Register of Therapeutic Goods entry for the exact Dicaris levamisole 150 mg tablet product has not been confirmed in available product information. Its precise Australian prescription classification and any Pharmaceutical Benefits Scheme subsidy also remain unconfirmed. Those uncertainties should not be replaced with assumptions based on the medicine's status in another country or on the status of a different levamisole product.

Our ordering policy does not require customers to submit a prescription for Dicaris. That is an operational checkout policy, not a statement that the exact product has a confirmed ARTG entry, a particular Australian scheduling classification or PBS eligibility. It also does not replace professional advice about whether levamisole is appropriate.

The Therapeutic Goods Administration accepts reports of suspected adverse events involving medicines. This safety-reporting pathway is separate from our ordering process and does not, by itself, confirm the registration status of a particular product.

Ordering and support from our catalogue

To order, select one of the available quantities of 16, 32, 48, 60, 76 or 92 tablets and proceed through our checkout. We show catalogue prices in Australian dollars. No prescription submission is required under our current ordering policy, but customers should still have a clear dosing plan and understand the monitoring requirements before purchasing.

Our support team is available 24/7 by email, online chat and phone. A pharmacist is also available for questions about the product strength, package quantities and general medicine information. Support can help clarify catalogue details, but it cannot diagnose symptoms or determine an individual treatment plan without an appropriate clinical assessment.

No specific delivery range is supplied in this guide, so an arrival date should not be assumed in advance. Confirm the applicable ordering and delivery details before completing checkout, particularly if treatment is time-sensitive. Do not delay urgent medical assessment while waiting for an online order.

A balanced final decision

Dicaris is a specific 150 mg levamisole oral tablet with one available strength and several package quantities. It may be relevant only when levamisole is appropriate for a clearly identified purpose. The fixed strength, uncertain product-specific Australian regulatory position and recognised risk of serious white blood cell suppression make it unsuitable for casual trial use or self-directed repeat courses.

Before choosing a pack, confirm the intended condition, dose, duration, need for blood-count monitoring and whether another formulation or antiparasitic medicine would be a better match. Pregnancy, breastfeeding, paediatric use, allergy to product ingredients and medicines that affect blood cells require particular attention. Once those points are settled, choose the package quantity that corresponds to the confirmed plan rather than selecting a larger pack based on an assumed future need.